Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

NCT05436223 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG: Human CD19Targeted T Cells Injection

Sponsor

Hrain Biotechnology Co., Ltd.

Collaborators

[object Object]